Lee Ann Baxter-lowe
ProfessorÂ
Pediatrics
University of Southern California
United States of America
Biography
"Dr Baxter-Lowe's research involves characterizing HLA polymorphism and determining its relevance in transplantation and human disease. In recent years she has been investigating the role of HLA antibodies in transplantation of solid organs and hematopoietic stem cells. Her laboratory has supported numerous single and multicenter clinical trials in transplantation and has been a core laboratory for the NIH Immune Tolerance Network. Her research has been reported in more than 125 scientific publications. Dr. Baxter-Lowe has also served as a clinical histocompatibility laboratory director and in this capacity has been involved in advancing histocompatibility testing and its clinical application. She has had a long-standing commitment to policy development and is currently serving as Chair of the Histocompatibility Committee of the United Network for Organ Sharing (UNOS) and is the facilitator for the Histocompatibility Workgroup for the 2012 National Consensus Conference on Kidney Paired Donation (KPD). She has served as a member or chair of numerous national and international committees in this field."
Research Interest
HLA antibodies in transplantation of solid organs and hematopoietic stem cells
Publications
-
Pidala J, Wang T, Haagenson M, Spellman SR, Askar M, Battiwalla M, Baxter-Lowe LA, Bitan M, Fernandez-Viña M, Gandhi M, Jakubowski AA. Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality. Blood. 2013 Jan 1:blood-2013.
-
Eapen M, Klein JP, Ruggeri A, Spellman S, Lee SJ, Anasetti C, Arcese W, Barker JN, Baxter-Lowe LA, Brown M, Fernandez-Vina MA. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood. 2013 Jan 1:blood-2013.
-
Baxter-Lowe LA, Kucheryavaya A, Tyan D, Reinsmoen N. CPRA for allocation of kidneys in the US: more candidates≥ 98% CPRA, lower positive crossmatch rates and improved transplant rates for sensitized patients. Human immunology. 2016 May 31;77(5):395-402.
